Atara Biotherapeutics Inc
ATRA
Get informed when a big investor buys or sells
+ FollowMarket Cap$94.7M
Close$
$-2.33
124.2% downside
Current Fair Value
124.2% downsideOvervalued by 124.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $94.70 Million |
|---|---|
| Enterprise Value | $96.10 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $2.61 |
| Beta | -0.29 |
| Outstanding Shares | 14,081,000 |
Return
| Return on Equity | 25.37% |
|---|---|
| Return on Assets | -47.34% |
| Return on Invested Capital | -50.80% |
Valuation & Multiples
| P/E Ratio | -15.63 |
|---|---|
| PEG | 14.1 |
| Price to Sales | 9.63 |
| Price to Book Ratio | -3.21 |
| Enterprise Value to Revenue | 4.88 |
| Enterprise Value to EBIT | -13.18 |
| Enterprise Value to Net Income | -11 |
| Total Debt to Enterprise | 0.1 |
| Debt to Equity | -0.26 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 21, 2026
EPS Estimate
$-0.33
Average shareholder expectationRevenue Estimate
$2.90 M
Average shareholder expectationNext Earnings Call
Expected Date
August 10, 2026
EPS Estimate
$-0.32
Average shareholder expectationRevenue Estimate
$2.55 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | 2000% |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 20.44%▲ 5.33% |
|---|---|
| Total Invested | $12.13M▼ 67.28% |
| Investors Holding | 34▼ 8.00% |
ESG Score
No data
About Atara Biotherapeutics Inc
CEO: Pascal Touchon